No Evidence of a Genetic Polymorphism in the Oxidative Metabolism of Midazolam

Clinical Pharmacokinetics

Volumn 15, Issue 5, 1988, Pages 319-325

  Kassai, Adam ^a   Toth, Georg ^a   Eichelbaum, Michel ^a   Klotz, Ulrich ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MIDAZOLAM;

ADULT; AEROBIC METABOLISM; CLINICAL ARTICLE; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HEREDITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

AGE FACTORS; ALCOHOL DRINKING; FEMALE; HALF-LIFE; HUMAN; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIDDLE AGE; OXIDATION-REDUCTION; POLYMORPHISM (GENETICS); SMOKING; SUPPORT, NON-U.S. GOV'T;

EID: 0023811841     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-198815050-00004     Document Type: Article

References (22)

1. Midazolam pharmacokinetics and pharmacodynamics during acute hypovolemia
2. Midazolam kinetics
3. Die Pharmakokinetik des Midazolam während verschiedener Anaesthesie-Bedingungen
4. Prolonged midazolam elimination half-life
5. Defective oxidation of drugs: pharmacokinetic and therapeutic implications
6. Defective N-oxidation of sparteine in man — a new pharmacogenetic defect
7. A family and population study of the general polymorphism of debrisoquine oxidation in a white British population
8. Effect of age, gender, and obesity on midazolam kinetics
9. 14C-midazolam in humans following oral dosing
10. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices
11. Genetically determined polymorphisms in drug oxidation
12. Ethnic differences in drug metabolism
13. Midazolam: the first water-soluble benzodiazepine — pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia
14. On the Kolmogorov-Smirnov test for normality with mean and variance unknown
15. Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation
16. Physiologic and temporal variation in hepatic elimination of midazolam
17. A new drug hydroxylation polymorphism in man: the incidence of mephenytoin hydroxylation deficient phenotypes in a European population study
18. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man
19. Midazolam: pharmacology and uses
20. Failure of critically ill patients to metabolise midazolam
21. Pharmacogenetic perspectives: genes, drugs and disease